Back to results
US 2016/0097099 A1Published application
Biomarkers for the molecular classification of bacterial infection
AssigneeDuke University
InventorsEphraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
Life of this patent
Estimating the term…
Abstract
Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
Claims12
A method of identifying and treating a subject suspected of having a bacterial blood stream infection (BSI), the method comprising:
- a) determining gene expression levels of at least two biomarkers in a peripheral blood cell sample of the subject, wherein the biomarkers are selected from any one of Tables 3-17;
- b) comparing the gene expression levels of the at least two biomarkers to standard gene expression levels wherein the standard gene expression levels correspond to the gene expression levels for the biomarkers in a control;
- c) identifying the subject as having a bacterial BSI if the gene expression levels of the biomarkers are different than the standard gene expression levels;
- and
- d) administering an effective amount of antibiotic therapy to treat the subject identified as having a bacterial BSI.
2 more elements
A method of distinguishing and treating Staphylococcus aureus blood stream infection (BSI) from Escherichia coli BSI in a subject suspected of having a bacterial infection, the method comprising:
- a) determining gene expression levels of at least two biomarkers in a peripheral blood cell sample of the subject, wherein the biomarkers are selected from any one of Tables 8 and 10 or Tables 3-6;
- b) comparing the gene expression levels of the at least two biomarkers to standard gene expression levels wherein the standard gene expression levels correspond to the gene expression levels for the biomarkers in a control;
- c) identifying the subject as having a S. aureus BSI if the gene expression levels of the biomarkers are different than the standard gene expression levels and identifying the subject as having an E. coli BSI if the gene expression levels of the biomarkers are the same as the standard gene expression levels;
- and
- d) administering an effective amount of appropriate antibacterial therapy to treat the subject identified as having a S. aureus BSI or E. coli.
2 more elements
Dependencies are inferred from the claim text.